Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

May 29, 2020

Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

May 22, 2020

Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

May 6, 2020

Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

April 27, 2020

Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma

April 1, 2020

Harpoon Therapeutics Appoints Two New Members to Its Board of Directors

March 12, 2020

Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update

March 5, 2020

Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update

February 20, 2020

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

November 26, 2019

Harpoon Therapeutics to Participate in the Piper Jaffray Healthcare Conference

November 21, 2019

Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoon’s BCMA-Targeting TriTAC®, and Expand Existing Discovery Collaboration

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2020. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations